Status:
RECRUITING
A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study is for people with cystic fibrosis who took part in a previous study with a medicine called BI 3720931. The main purpose of this study is to monitor the long-term health of participants who...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Trial participants who participated in a previous BI sponsored trial with BI 3720931 and have received any dose of BI 3720931, or matching placebo
- Signed and dated written informed consent in accordance with International Council for Harmonisation (ICH)-Good Clinical Practice (GCP) and local legislation prior to admission to the trial
- There are no exclusion criteria for enrolment into the trial.
Exclusion
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 24 2048
Estimated Enrollment :
285 Patients enrolled
Trial Details
Trial ID
NCT06962852
Start Date
May 20 2025
End Date
November 24 2048
Last Update
December 19 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
HOP Gui de Chauliac
Montpellier, France, 34295
2
HOP Necker
Paris, France, 75015
3
Istituto G. Gaslini
Genova, Italy, 16147
4
Osp. Pediatrico Bambin Gesù
Roma, Italy, 00165